Tag: fabry disease market demand

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Fabry Disease Industry By 2029?

Recent years have seen considerable expansion in the Fabry disease market size. It is projected to increase from $2.1 billion in 2024 to $2.26 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.2%. The appreciable growth observed in the past period is the result of enhanced recognition and detection of uncommon diseases, the evolution of specialized healthcare infrastructure, governmental incentives and the designation of orphan drugs, amplified funding for research into rare diseases, and the initial introductions of therapy sessions.

Anticipations are high for significant expansion in the Fabry disease market size in the subsequent years. The projections indicate a growth to “$3.04 billion in 2029” with a compound annual growth rate (CAGR) of 7.7%. This predicted rise in the coming period is largely credited to factors like augmented newborn screening programs, administrative backing for orphan and unusual disease medications, broadened healthcare access, the evolution of telemedicine and remote care, and increased need for personalized medicine. Noteworthy transitions expected in the forecast duration include embracing enzyme replacement therapy, progression in genetic testing, utilization of AI and digital equipment for preemptive detection, AI-infused diagnostic algorithms, and advancements in gene therapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

What Growth-Enabling Forces Are Impacting The Fabry Disease Market?

The expansion of the fabry disease market is anticipated to be spurred by an increasing emphasis on personalized medicine. This treatment approach, which is specifically tailored to an individual’s genes, environment, and lifestyle for improved results, is seeing a rise in focus due to its ability to enhance treatment efficacy and minimize side effects. Personalized medicine is instrumental in customizing treatment strategies in line with a patient’s particular genetic mutation and severity of disease, positively impacting results and reducing unwarranted side effects. For example, in February 2024, The Personalized Medicine Coalition, a non-profit organization based in the US, was witness to the FDA approving 16 new personalized treatments for patients suffering from rare diseases in 2023, marking a substantial growth from the six approvals in 2022. Thus, the burgeoning emphasis on personalized medicine is fueling the expansion of the fabry disease market.

How Is The Fabry Disease Market Segmented Across Key Categories?

The fabry disease market covered in this report is segmented –

1) By Type: Type 1, Type 2, Other Types

2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments

3) By Diagnosis: Blood Test, Genetic Test, Parenteral Test, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease

2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease

3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease

What Key Trends Are Driving Growth In The Fabry Disease Market?

Leading firms in the Fabry disease market are directing their attention to crafting innovative treatments such as PEGylated enzyme replacement therapy (ERT). These advancements aim to heighten therapy effectiveness, better patient compliance, and lower immunogenic reactions related to traditional ERTs. PEGylated enzyme replacement therapy (ERT) is a refined version of the standard ERT. It attaches polyethylene glycol (PEG) chains to the enzyme, thereby increasing stability, extending the duration in the body, and minimizing immune system responses. For example, Chiesi Global Rare Diseases- a division of the Chiesi Group based in Italy- announced in May 2023, that the US Food and Drug Administration (FDA) approved PRX-102 (pegunigalsidase alfa) for treating adult patients with Fabry disease. This approval was backed by a comprehensive clinical program, which incorporated more than 140 patients and had a long-term follow-up of 7.5 years. The program demonstrated the therapy’s effectiveness in decreasing renal Gb3 deposits and protecting kidney function, while also exhibiting an agreeable safety record.

Which Firms Are Driving Innovation Within The Fabry Disease Market?

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

How Do Regional Dynamics Influence The Fabry Disease Market Performance?

North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24218&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Fabry Disease Market Growth in 2025?

In the past few years, the market size for Fabry disease has been witnessing significant growth. The market, which is projected to expand from $2.10 billion in 2024 to $2.28 billion in 2025, is expected to have a compound annual growth rate (CAGR) of 8.2%. This substantial rise during the historic period can be credited to factors like the surge in awareness and diagnosis of uncommon diseases, development in specialized healthcare facilities, government incentives and rare drug nominations, growth in funding for rare disease research, and the initial release of therapies.

What Is the Forecast for the Fabry Disease Market Size Through 2029?

The market size of Fabry disease is anticipated to experience strong expansion in the upcoming years, skyrocketing to $3.10 billion by 2029, with a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this incline during the forecast period include the enlarging scope of newborn screening programs, legislative support for orphan and rare disease medication, increased accessibility of healthcare services, the surge of telemedicine and distance health care, and the escalating requirement for tailor-made medicine. Key trends during this period are the utilization of enzyme replacement therapy, advancements in genetic examination, incorporation of AI and digital mechanisms for preliminary detection, AI-driven diagnostic systems, and breakthroughs in gene therapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

What are the Key Market Players in Fabry Disease Market and How They’re Evolving?

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

What Are the Primary Growth Drivers in the Fabry Disease Market?

The expansion of the Fabry disease market is projected to be fueled by an increased emphasis on personalized medicine. This approach of medical treatment considers a person’s genes, environment, and lifestyle to customize medical care and therapies specifically for them, leading to better outcomes. The surge in focus on personalized medicine is owing to its capacity to enhance treatment efficiency and curb side effects by adapting therapies to meet individual patient needs. Personalized medicine empowers the creation of treatment plans based on a patient’s unique genetic mutation and disease severity, elevating outcomes and reducing unnecessary side effects. For example, the U.S.-based non-profit organization, the Personalized Medicine Coalition, played a significant role. In 2023, the FDA granted approval for 16 new personalized treatments for those with rare diseases, a marked increase compared to the six approvals in 2022. Consequently, the burgeoning emphasis on personalized medicine underpins the growth of the fabry disease market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

What Are the Leading Segments in the Global Fabry Disease Industry?

The fabry disease market covered in this report is segmented –

1) By Type: Type 1, Type 2, Other Types

2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments

3) By Diagnosis: Blood Test, Genetic Test, Parenteral Test, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegment:

1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease

2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease

3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease

What Are the Key Market Trends in the Fabry Disease Industry?

The focus of leading firms in the Fabry disease market is on the creation of novel therapies such as PEGylated enzyme replacement therapy (ERT) to improve efficacy of treatment, patient adherence, and minimize the immunogenic reactions in relation to traditional ERTs. PEGylated enzyme replacement therapy (ERT) is an advanced version of standard ERT, where polyethylene glycol (PEG) chains are combined with the enzyme to enhance its stability, extend its lifespan in the body, and reduce the immune system’s reactions. For instance, in May 2023, Chiesi Global Rare Diseases, a segment of the Italy-based Chiesi Group, disclosed that the U.S. Food and Drug Administration (FDA), a US government organization, gave approval for PRX-102 (pegunigalsidase alfa) for treating adult Fabry disease patients. This approval comes on the back of an intensive clinical program involving over 140 patients and long-term tracking for up to 7.5 years, revealing the effectiveness of the therapy in minimizing renal Gb3 deposits and preservation of kidney functionality while showcasing a promising safety profile.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

What Is the Regional Outlook for the Fabry Disease Market?

North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24218&type=smp

This Report Delivers Insight On:

1. How big is the fabry disease market, and how is it changing globally?

2. Who are the major companies in the fabry disease market, and how are they performing?

3. What are the key opportunities and risks in the fabry disease market right now?

4. Which products or customer segments are growing the most in the fabry disease market?

5. What factors are helping or slowing down the growth of the fabry disease market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

#How Fast Is The Fabry Disease Market Expected to Grow Between 2025 And 2029?#_x000D_

Over the past years, the market size for Fabry disease has witnessed a significant surge. It is anticipated to rise from $2.10 billion in 2024 to $2.28 billion in 2025, with a compound annual growth rate (CAGR) of 8.2%. The expansion during the historical period is credited to heightened consciousness and identification of rare conditions, evolution in specialized healthcare facilities, government incentives along with orphan drug designations, escalated funding for rare disease investigation, and the introductory launch of treatments._x000D_

_x000D_

In the coming years, the market size for Fabry disease is anticipated to witness substantial growth, with projections estimating a value of $3.10 billion by 2029, reflecting a compound annual growth rate (CAGR) of 8.0%. This anticipated growth during the forecast period can be linked to several factors, such as broader newborn screening programs, regulatory backing for drugs related to rare and orphan diseases, the extension of healthcare coverage, burgeoning telemedicine and remote care, and an increasing demand for personalized healthcare. Key trends that will shape the forecast period include the embracement of enzyme replacement therapy, progress in genetic testing, the application of AI and digital tools for early diagnosis, the use of AI-driven diagnostic algorithms, and advancements in gene therapy._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp_x000D_

_x000D_

#How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Fabry Disease Market?#_x000D_

The fabry disease market is predicted to experience growth as there is an increasing emphasis on personalized medicine. This therapeutic approach utilizes information about an individual’s genetic makeup, environment, and lifestyle to custom-tailor healthcare and treatments, leading to better results. The escalating interest in personalized medicine is due to its potential in enhancing treatment efficacy and reducing side effects by catering therapies to the unique requirements of each patient. Utilizing personalized medicine enables the creation of treatment strategies based on the specific genetic mutation and the severity of the disease in a patient, enhancing results and reducing unnecessary side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization highlighted that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases. This was a significant increase compared to the six approvals in 2022. Consequently, the rising emphasis on personalized medicine contributes to the growth of the fabry disease market._x000D_

_x000D_

#Which Segments in the Fabry Disease Offer the Most Growth?#_x000D_

The fabry disease market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Type 1, Type 2, Other Types_x000D_

2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments_x000D_

3) By Diagnosis: Blood Test, Genetic Test, Parenteral Test, Other Diagnosis_x000D_

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy_x000D_

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users_x000D_

_x000D_

Subsegment:_x000D_

_x000D_

1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease_x000D_

2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease_x000D_

3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp_x000D_

_x000D_

#What Are the Fastest-Growing Geographies in the Fabry Disease Market?#_x000D_

North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Current Market Growth and Trends in the Fabry Disease Industry?#_x000D_

Leading enterprises in the fabry disease market are concentrating on creating innovative treatments like PEGylated enzyme replacement therapy (ERT) in order to enhance the effectiveness of the therapy, improve patient adherence, and minimize the immunogenic responses related to traditional ERTs. PEGylated ERT is a modified version of the conventional ERT where polyethylene glycol (PEG) chains are attached to the enzyme, improving its stability, extending its circulation period in the body, and reducing immune system responses. For example, Chiesi Global Rare Diseases, a unit of Italy-based Chiesi Group, announced in May 2023 the approval from the U.S. Food and Drug Administration (FDA) for PRX-102 (pegunigalsidase alfa) for treating adult patients with Fabry disease. The endorsement is backed by a compelling clinical program that involved over 140 patients and a long-term follow-up of nearly 7.5 years, showing the treatment’s effectiveness in lowering renal Gb3 deposits and preserving kidney function, while also having a promising safety profile._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report_x000D_

_x000D_

#What Are the Key Elements That Define the Fabry Disease Market?#_x000D_

Fabry disease is a rare genetic disorder caused by a deficiency in the enzyme alpha-galactosidase A, leading to the accumulation of fat in the body’s cells and organs. The purpose of treatment is to manage symptoms, reduce organ damage, and improve the quality of life for affected individuals._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=24218&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model